Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
New preclinical data demonstrate that SIL204 treatment produced statistically significant upregulation of FAS (CD95), the immune “death receptor,” and statistically significant downregulation of...
-
Vantage Biosciences completes enrollment in the Phase 2 SeeClear study of oral oruvestat in non-proliferative diabetic retinopathy.
-
Splash expands its exclusive global license for CannEpil® to include veterinary applications, creating a second regulated pharmaceutical development platfo
-
Noom Health is partnering with Levrx to optimize metabolic health/ GLP-1 programs directly through existing pharmacy benefit platforms
-
Successful initiation of the Phase 2/3 clinical trial of SIL204 at Tel Aviv Sourasky Medical Center (“TASMC” or “Ichilov”), one of Israel’s largest and most prominent academic medical centers, clears...
-
Oktopi has received follow-on funding from the Gates Foundation, extending its original grant to advance OktoPilot, the platform's AI-agent
-
AscellaHealth Named ACAP Preferred Vendor to Advance Specialty Pharmacy Strategy, Cost Containment and Care Management
-
Funding to advance AI-native drug R&D engine and pipelines, including MDR-001, an oral GLP-1 small-molecule in Phase III clinical trials in China.
-
Austin, TX, USA, July 01, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Human Fibrinogen Concentrate Market Size, Trends and Insights By Form...
-
Regulatory approvals, strategic acquisitions, clinical development milestones, and financing initiatives are highlighting continued activity across the bio